Deinove takes option on Redx Pharma antibiotic portfolio

22 March 2018
2019_biotech_test_vial_discovery_big

French biotech company Deinove (Euronext Growth Paris: ALDEI) has signed a license option agreement with British firm Redx Pharma (AIM: REDX) for the acquisition of its first-in-class anti-infective program, novel bacterial topoisomerase inhibitor (NBTI).

Although no financial terms of the deal were provided, it is good news for Redx, which only last November exited administration as a going concern. However, the company’s shares dipped 2.2% to 11.00 pence in mid-morning trading.

Redx announced in March 2017 that it would concentrate on the development of its cancer and fibrosis products and would look to partner its anti-infective programs.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology